Description
Book SynopsisFlow Cytometry of Hematological Malignancies
Flow cytometric analysis is often integral to the swift and accurate diagnosis of leukemias and lymphomas of the blood, bone marrow, and lymph nodes. However, in the fast-moving and expanding field of clinical hematology, in can be challenging to remain up to speed with the latest biological research and technological innovations. Flow Cytometry of Hematological Malignancies has been designed to provide all those working in hematological oncology with a practical, cutting-edge handbook, featuring clear and fully illustrated guidance on all aspects of cytometry's role in diagnosis and analysis. This essential second edition includes:
- Explorations of more than 70 antigens
- Full-color illustrations throughout
- New descriptions of recently discovered markers
- WHO classifications of hematological neoplastic diseases
- Helpful tips for result interpretation and analysis
Featuring all this and
Table of Contents
Foreword to the Second Edition xi
by Michael J. Borowitz
Foreword to the First Edition xii
by Maryalice Stetler-Stevenson
Foreword to the First Edition xiii
by Bruno Brando
Preface to the Second Edition xv
Preface to the First Edition xvi
Abbreviations xvii
1 Antigens 1
Clustered (CD) Antigens
CD1 3
CD2 5
CD3 8
CD4 17
CD5 21
CD7 24
CD8 26
CD10 30
CD11b 35
CD11c 38
CD13 40
CD14 44
CD15 46
CD16 49
CD19 52
CD20 55
CD22 59
CD23 61
CD24 64
CD25 66
CD26 67
CD27 69
CD28 70
CD30 71
CD33 73
CD34 77
CD38 79
CD43 81
CD45 82
CD45 Isoforms 87
CD49 90
CD56 93
CD57 96
CD61 97
CD62L 98
CD64 99
CD65 101
CD66c 102
CD71 103
CD79 104
CD81 107
CD103 108
CD117 110
CD123 112
CD138 113
CD200 114
CD305 116
CD307 (IRTA) Antigen Family 117
CD371 118
Non clustered (or primarily known with other names) antigens Bcl‐2 Protein 119
Chemokines and Chemokine Receptors 121
CRLF2 128
Cytotoxic Proteins 129
HLA‐DR 130
Immunoglobulins 132
KIR, CD158 isoforms 136
Myeloperoxidase (MPO) 139
NG2 140
PCA‐1 141
ROR1 141
SLAM Molecules and SLAM‐associated Protein (SAP) 142
SOX11 144
T‐cell Receptor (TCR) 145
Terminal Deoxy‐nucleotidyl‐transferase (TdT) 148
Toll‐like Receptors (TLR) 150
VS38 151
ZAP‐70 152
2 Diseases 155
Myeloproliferative neoplasms 157
Chronic myeloid leukemia (CML) 157
Myeloproliferative neoplasms other than CML 160
Chronic neutrophilic leukemia (CNL) 160
Polycythemia vera (PV) 160
Primary myelofibrosis (PMF) 160
Essential thrombocythemia (ET) 160
Chronic eosinophilic leukemia (CEL) 161
Mastocytosis 162
Acute mast‐cell leukemia (AMCL) 162
Chronic mast‐cell leukemia (CMCL) 163
Myelomastocytic leukemia (MML) 163
Myelodysplastic/myeloproliferative neoplasms 164
Chronic myelomonocytic leukemia (CMML) 164
Other myelodysplastic/myeloproliferative neoplasms and related conditions 167
Juvenile myelomonocytic leukemia (JMML) 167
Atypical CML bcr/abl negative (ACML) 167
RAS‐associated autoimmune leukoproliferative disorder (RALD) 167
Myelodysplastic syndromes 168
Myeloid neoplasms with germline predisposition 171
Acute myeloid leukemias 172
AMLs with recurrent genetic anomalies 173
AMLs with chromosomal anomalies 173
AMLs with gene mutations 180
Relationships between genotype and phenotype in cases of AML not recognized as separate entities in WHO 2017 181
AMLs with myelodysplasia‐related changes (AML‐MRC) 182
AMLs not otherwise specified 182
AML with minimal differentiation 182
AML without maturation 183
AML with maturation 183
Acute myelomonocytic leukemia (AMMoL) 183
Acute monoblastic and monocytic leukemia (AMoL) 184
Pure erythroid leukemia (PEL) 185
Acute megakaryoblastic leukemia (AMKL) 186
Acute basophilic leukemia (ABL) 188
Myeloid proliferations associated with Down syndrome 188
Transient abnormal myelopoiesis (TAM) 189
AMLs in patients with Down syndrome 189
Blastic plasmacytoid dendritic cell neoplasm (BPDCN/PDCL) 189
Acute leukemias with ambiguous lineage attribution (ALAL) 192
Acute undifferentiated leukemias (AUL) 192
Mixed phenotype acute leukemias (MPAL) 192
Neoplastic diseases of B and T lymphatic precursors 194
B lymphoblastic leukemia/lymphoma, not otherwise specified (B‐ALL/LBLnos) 195
B lymphoblastic leukemia/lymphoma with recurrent genetic anomalies 197
Relationships between genotype and phenotype in cases of B‐ALL not recognized as separate entities in WHO 2017 201
T lymphoblastic leukemia/lymphoma (T‐ALL/LBL) 202
Early T‐cell precursor lymphoblastic leukemia (ETP‐ALL) 205
NK lymphoblastic leukemia/lymphoma (NK‐ALL/LBL) 205
Neoplastic diseases of mature B cells 206
Chronic lymphocytic leukemia/small
lymphocytic lymphoma (B‐CLL/SLL) 206
Familial B‐CLL 215
Richter syndrome 215
Monoclonal B‐cell lymphocytosis (MBL) 216
CLL‐like monoclonal B lymphocytosis 216
Non‐CLL‐like monoclonal B lymphocytosis 216
B‐cell prolymphocytic leukemia (B‐PLL) 216
Lymphoplasmacytic lymphoma (LPL) 218
Heavy chain disease (HCD) 221
γ heavy chain disease 222
μ heavy chain disease 222
α heavy chain disease 222
Hairy cell leukemia (HCL) 222
Hairy cell leukemia, variant (HCL‐v) 226
Hairy cell leukemia, Japanese variant (HCL‐J) 227
Splenic diffuse red pulp lymphoma (SDRPL) 227
Marginal zone lymphomas (MZL) 228
Nodal marginal zone lymphoma (NMZL) 229
Splenic marginal zone lymphoma (SMZL) 230
Extranodal marginal zone lymphoma (EMZL/MALToma) 232
Clonal B‐cell lymphocytosis with MZL‐like phenotype (CBL‐MZ) 233
Follicular lymphoma (FCL) 234
Testicular follicular lymphoma 237
Duodenal type follicular lymphoma 237
Pediatric type follicular lymphoma 237
Primitive cutaneous follicular lymphoma (PCFL) 237
Large B‐cell lymphoma with IRF4 rearrangement 237
Mantle‐cell lymphoma (MCL) 237
Blastic mantle‐cell lymphoma (BMCL) 240
Leukemic non nodal mantle‐cell lymphoma 240
DLBCL not otherwise specified (DLBCLnos) 240
CD5(+) diffuse large cell lymphoma (CD5(+) DLBCL) 243
T‐cell/histiocyte‐rich B‐cell lymphoma (THRLBCL) 243
Primary DLBCL of the CNS (PCNSL) 244
Primary cutaneous DLBCL, “leg type” 244
EBV(+) DLBCLnos 244
DLBCL associated with chronic inflammation (PAL) 245
Fibrin associated DLBCL 245
Lymphomatoid granulomatosis (LYG) 245
Primary mediastinal B‐cell lymphoma (PMBCL) 245
Intravascular large B‐cell lymphoma (IVBCL) 246
ALK‐positive large cell lymphoma (ALK(+) LBCL) 246
Plasmablastic lymphoma (PBL) 247
Primary effusion lymphoma (PEL) 247
HHV8‐associated lymphoproliferative disorders 247
HHV8‐positive DLBCL 248
HHV8‐positive germinotropic lymphoproliferative disorder 248
Burkitt lymphoma (BL) 248
Burkitt leukemia with immature phenotype 250
Burkitt‐like lymphoma with 11q aberrations 251
High‐grade B‐cell lymphoma (HGBL) 251
Plasma cell neoplasms 251
Monoclonal gammopathies of undetermined significance (MGUS) 253
Multiple myeloma (MM) 253
Plasma cell leukemia (PCL) 257
Neoplastic diseases of mature T and NK cells 258
T‐cell prolymphocytic leukemia (T‐PLL) 258
T‐cell large granular lymphocytic leukemia (T‐LGL) 261
Chronic lymphoproliferative disorders of NK cells (CLPD‐NK/CNKL) 263
Aggressive NK‐cell leukemia (ANKL) 266
Adult T‐cell leukemia/lymphoma (ATLL) 266
Extranodal NK/T-cell lymphoma, “nasal type” (ENKTL) 269
Intestinal T‐cell lymphomas (ITCL) 270
Enteropathy‐associated T‐cell lymphoma (EATCL) 270
Monomorphic epitheliotropic intestinal T‐cell lymphoma (MEITL) 272
Indolent gastro‐intestinal T lymphoproliferative disorder (indolent GI T‐LPD) 273
Hepatosplenic T‐cell lymphoma (HSTCL) 273
Subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) 275
Mycosis fungoides (MF) 275
Sezary syndrome (SS) 277
Primary cutaneous CD30(+) lymphoproliferative disorders 279
Lymphomatoid papulosis (LyP) 279
Primary cutaneous anaplastic T‐cell lymphoma (pcALCL) 279
Primary cutaneous peripheral T‐cell lymphoma (PTCL) 280
Primary cutaneous TCRγδ(+) T‐cell lymphoma (PCGD‐TCL) 280
Primary cutaneous CD8(+) aggressive epidermotropic cytotoxic T‐cell lymphoma (PCAETL) 280
Primary cutaneous acral CD8(+) T‐cell lymphoma (PCATCL) 280
Primary cutaneous lymphoma of the medium/small CD4(+) T cells (PCSM‐TCL) 281
Peripheral T‐cell lymphoma, not otherwise specified (PTCLnos) 281
Nodal lymphomas of follicular T‐helper derivation 283
Angioimmunoblastic T‐cell lymphoma (AITL) 283
Follicular T‐cell lymphoma (FTCL) 285
Nodal PTCL with follicular T‐helper phenotype 285
Anaplastic large cell lymphoma ALK(+) (ALCL ALK(+)) 285
Anaplastic large cell lymphoma ALK(‐) (ALCL ALK(‐)) 288
Breast implant–associated anaplastic large cell lymphoma (biaALCL) 288
Hodgkin lymphomas 289
Classic Hodgkin lymphoma (CHL) 289
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) 290
Neoplastic diseases of histiocytic and dendritic cells 291
Histiocytic sarcoma (HS) 292
Langerhans cell histiocytosis (LCH) 292
Indeterminate dendritic cell tumor (IDCT) 292
Interdigitating dendritic cell sarcoma (IDCS) 292
Follicular dendritic cell sarcoma (FDCS) 292
Erdheim–Chester disease (EDC) 292
3 Appendix 293
Acute leukemias not recognized by the 2017 WHO classification 294
Acute leukemia of myeloid/NK precursors (M/NK‐AL) 294
Acute leukemia of myeloid dendritic cells (MDCL) 294
Acute leukemia of Langerhans cells 294
Composite lymphomas 294
Hypereosinophilic syndrome (HES), lymphocyte variant 295
Indolent T lymphoblastic proliferations (iT‐LBP) 295
Polyclonal lymphocytoses of B lymphocytes 298
Persistent polyclonal B‐cell lymphocytosis (PPBL) 298
Persistent polyclonal CD5(+) B‐cell lymphocytosis 298
Persistent polyclonal B‐cell lymphocytosis, Japanese (hairy) variant 298
Polyclonal plasmacytoses 299
Small round (blue) cell tumors (SR(B)CT) 300
References 301
Index 429
